Avinger, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Nabeel P. Subainati CPA
- Full Time Employees
- 68
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 400 Chesapeake Drive Redwood City CA United States of America 94063
- IPO Date
- Jan 30, 2015
- CIK
- 0001506928
- Website
- avinger.com
- Similar Companies
- Business
- Avinger, Inc. is a commercial-stage medical device company headquartered in Redwood City, California, specializing in the design, manufacture, and sale of image-guided, catheter-based systems for the diagnosis and treatment of peripheral artery disease (PAD). The company’s core products are based on its proprietary Lumivascular platform, which combines advanced optical coherence tomography (OCT) imaging with therapeutic catheter devices to enable real-time, intravascular visualization and precision intervention. Its main product suite includes the Lightbox imaging console, Ocelot and Tigereye catheters designed for penetrating chronic total occlusions, and the Pantheris image-guided atherectomy device for precise plaque removal in PAD patients. The company also develops products targeting coronary artery disease. In 2024, Avinger announced a strategic partnership and up to $15 million in equity funding from Zylox-Tonbridge Medical Technology Co., Ltd., a leading Chinese medical device firm specializing in neuro- and peripheral-vascular interventions. This partnership includes a licensing agreement to access the Greater China market, technology transfer for cost-efficient manufacturing to support global sales, and opportunities for reciprocal product distribution in the U.S. and Germany. Concurrently, Avinger focused on cost reduction and streamlined operations, reducing headcount by 24% to concentrate on higher volume accounts and coronary product development, with plans for FDA IDE submission of a coronary CTO-crossing device. Despite these strategic initiatives, Avinger’s shareholders approved a liquidation plan in early 2025, and the company executed an assignment for the benefit of creditors with plans for voluntary dissolution and liquidation. This significant operational change reflected a strategic pivot from PAD products to coronary disease devices and accompanied workforce reductions, including the termination of employees involved in PAD sales and manufacturing. Historically, Avinger primarily operated in the United States and Germany, serving vascular disease treatment markets, with recent expansions aiming at the Greater China region through strategic partnerships. Founded in 2007, the company has developed a unique position in the vascular treatment space with its image-guided catheter technologies but faced major restructuring and dissolution decisions in 2025.
Avinger, Inc. Executes Assignment for the Benefit of Creditors; Announces Receipt of Nasdaq Delisting Notice
Avinger, Inc. (AVGR) Q3 2024 Earnings Call Transcript
Avinger (AVGR) Reports Q3 Loss, Tops Revenue Estimates
Avinger Reports Third Quarter 2024 Results
Avinger to Announce Third Quarter 2024 Results on November 7, 2024
Avinger Releases Updated Data From IMAGE-BTK in Webinar Featuring Key Opinion Leaders in the Field of Vascular Intervention
Avinger Announces Issuance of New U.S. Patent and Receives Notices of Allowance for Five Additional U.S. Patents
Avinger (AVGR) Launches Pantheris LV to Boost PAD Treatment
Avinger Initiates Full Commercial Launch of Pantheris LV Image-Guided Atherectomy Device
Avinger, Inc. (AVGR) Q2 2024 Earnings Call Transcript
Avinger (AVGR) Reports Q2 Loss, Lags Revenue Estimates
Avinger Reports Second Quarter 2024 Results
Avinger Appoints Thomas P. Davis, MD, FACC as Chief Medical Officer
Avinger to Announce Second Quarter 2024 Results on August 8, 2024
Avinger Announces Closing of up to $24 Million Public Offering
Avinger Increases Focus on Coronary Development, Reduces Operating Costs of Peripheral Business
Are Medical Stocks Lagging Avinger (AVGR) This Year?
Avinger Announces Conversion of $11 Million of CRG Debt into Preferred Equity
Avinger, Inc. (AVGR) Q1 2024 Earnings Call Transcript
Avinger Reports First Quarter 2024 Results